News & Trends - Pharmaceuticals

MA highlights regional development opportunities for medicines at export review

Health Industry Hub | February 12, 2020 |
[Total: 1    Average: 4/5]

Medicines Australia appeared before Parliament’s Joint Standing Committee on Trade and Investment Growth Inquiry into supporting Australia’s exports and attracting investment.

Medicines Australia CEO Ms Elizabeth de Somer said this inquiry provides a timely opportunity to reiterate how the Australian innovative medicines, biotherapeutics and vaccines industry can grow Australia’s exports and strengthen trade and investment to build a stronger and more resilient economy.

“There is a real and valuable opportunity to boost the contribution of Australia’s innovative medicines industry, encouraging foreign investment and trade, thus driving economic growth and prosperity.

“To increase foreign investment in Australia’s innovative medicines sector, the Government needs to better incentivise R&D, ensure intellectual property provisions are strong and competitive and harmonise the regulatory frameworks for clinical trials.

“Australia has an advantage over other regional centres because of the high quality and reliability of our health care system, the extraordinary talent in our scientists, researchers and clinicians, first class hospitals and medical infrastructure, as well as reliable rules of law and internationally recognised regulatory practices.

“However, the opportunities we are missing arise from such things as fragmented and onerous regulatory barriers for clinical research across the states and territories and lack of recognition of how to harness the potential,” said Ms de Somer.

Register FREE to receive the latest news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

“Clinical trials capacity and capability, as well as our talent for discovering, developing and delivering advanced technologies and services, which could be offered regionally, and globally, should be identified as an emerging export opportunity in the same way that education is considered a great Australian export,” she said.

During the inquiry, Ms de Somer highlighted how policy development, focused on growing Australia’s domestic capabilities and economic resilience, is needed and there is no better place to start than in clinical research and development.

“Any policies designed to encourage trade and investment must also ensure that all Australians continue to have access to high quality, safe, effective and cost-effective medicines and that Australia boosts our international competitiveness to incentivise the presence of industry,” said Ms de Somer.

“The potential opportunities for trade and investment of innovative precision medicines will only be realised through reforms to domestic approval and funding models and under new international trade and investment frameworks.

“Investment growth in Australia will see improvements in R&D, increased exports and the employment of highly skilled Australians,” said Ms de Somer

Enhance corporate branding and boost thought leadership to attract and retain quality employees. Health Industry Hub is the only one-stop-hub connecting Australia’s Pharma, MedTech, and Biotech industry professionals. Get started with our digital media solutions developed by industry for industry.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Pharmaceuticals

First immunotherapy PBS listed in small cell lung cancer - Pharma News

First immunotherapy treatment PBS listed in small cell lung cancer

Health Industry Hub | February 19, 2020 |

Pharma News: Effective 1 March 2020 the first immunotherapy treatment for small cell lung cancer (SCLC) will be available on […]

More


News & Trends - Medical Technology

Blood test to improve ovarian cancer diagnosis - MedTech News

Blood test to improve ovarian cancer diagnosis

Health Industry Hub | February 19, 2020 |

MedTech News: Australian researchers have developed a simple blood test that measures the body’s own immune response to improve diagnosis […]

More


Medical

The largest healthcare event in the region - Australian Healthcare Week - Medical News

Don’t miss the largest healthcare event in the region – Australian Healthcare Week

Health Industry Hub | February 19, 2020 |

Health Industry Hub is proud to partner with and support the free-to-attend 10th Annual Australian Healthcare Week Expo, held March […]

More


News & Trends - Pharmaceuticals

BMS announces new 5-year data in advanced renal cell carcinoma - Pharma News

BMS announces new 5-year data in advanced renal cell carcinoma

Health Industry Hub | February 19, 2020 |

Pharma News: Bristol-Myers Squibb announced five-year follow-up study results demonstrating that Opdivo (nivolumab) treatment delivers superior overall survival (OS) and […]

More